The Seville expert workshop for progress in posttransplant lymphoproliferative disorders.

: Posttransplant lymphoproliferative disorders (PTLDs) are associated with significant morbidity and mortality among solid-organ transplant patients, but approaches to diagnosis and management vary considerably. An international multidisciplinary panel evaluated current understanding of risk factors and classification systems and developed recommendations to aid in PTLD prevention. We considered evidence on PTLD risk factors including Epstein-Barr virus serostatus and immunosuppression and identified knowledge gaps for future research. Recommendations address prophylactic and preemptive strategies to minimize PTLD development, including modulation of immunosuppression and antiviral drug regimens. Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD.

[1]  M. Michaels,et al.  Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  C. Printz Advances in childhood cancers , 2012, Cancer.

[3]  W. Klapper,et al.  Plasmablastic Posttransplant Lymphoma: Cytogenetic Aberrations and Lack of Epstein-Barr Virus Association Linked With Poor Outcome in the Prospective German Posttransplant Lymphoproliferative Disorder Registry , 2012, Transplantation.

[4]  G. Salles,et al.  Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. , 2012, The Lancet. Oncology.

[5]  Sonali M. Smith,et al.  Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era , 2011 .

[6]  B. Gärtner,et al.  Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases , 2011, Haematologica.

[7]  A. Kirk,et al.  Sirolimus Enhances the Magnitude and Quality of Viral‐Specific CD8+ T‐Cell Responses to Vaccinia Virus Vaccination in Rhesus Macaques , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  Jie Zheng,et al.  Infection and malignancy after pediatric heart transplantation: the role of induction therapy. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  Dolca Thomas,et al.  An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients , 2010, Transplantation.

[10]  A. Pavie,et al.  Adapted Management of EBV Reactivation After Solid Organ Transplantation: An Effective Prevention of Post Transplantation Lymphoproliferative Disorders (PTLD). Results of the Largest Prospective Study on 251 Patients , 2010 .

[11]  G. Opelz,et al.  Pediatric Kidney Transplantation: Analysis of Donor Age, HLA Match, and Posttransplant Non-Hodgkin Lymphoma: A Collaborative Transplant Study Report , 2010, Transplantation.

[12]  K. Mucha,et al.  Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  R. Marcus,et al.  Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines , 2010, British journal of haematology.

[14]  B. McCrindle,et al.  Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  R. Marcus,et al.  Diagnosis of post‐transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines , 2010, British journal of haematology.

[16]  M. Gulley,et al.  Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative Disorder , 2010, Clinical Microbiology Reviews.

[17]  G. Opelz,et al.  Impact of HLA Mismatching on Incidence of Posttransplant Non-Hodgkin Lymphoma After Kidney Transplantation , 2010, Transplantation.

[18]  Scott E. Smith,et al.  Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Kaldor,et al.  Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study , 2010, BMJ : British Medical Journal.

[20]  G. Mazariegos,et al.  Chronic high Epstein–Barr viral load carriage in pediatric small bowel transplant recipients , 2009, Pediatric transplantation.

[21]  A. Morgans,et al.  Posttransplant lymphoproliferative disorder following kidney transplant. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  Gerhard Opelz,et al.  C3 polymorphisms and allograft outcome in renal transplantation. , 2009, The New England journal of medicine.

[23]  M. Kojima,et al.  Age‐related EBV‐associated B‐cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entity , 2009, Pathology international.

[24]  J. Preiksaitis,et al.  Epstein‐Barr Virus and Posttransplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  G. Opelz,et al.  Epidemiology of Pretransplant EBV and CMV Serostatus in Relation to Posttransplant Non-Hodgkin Lymphoma , 2009, Transplantation.

[26]  W. Irish,et al.  Epidemiologic critique of literature on post‐transplant neoplasms in solid organ transplantation , 2009, Clinical transplantation.

[27]  T. Larson,et al.  Posttransplant Lymphoproliferative Disorder Following Pancreas Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  J. Kaldor,et al.  Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. , 2009, Blood.

[29]  C. Macedo,et al.  The Impact of EBV Load on T-Cell Immunity in Pediatric Thoracic Transplant Recipients , 2009, Transplantation.

[30]  L. Danziger-Isakov,et al.  Hematologic complications of anti‐CMV therapy in solid organ transplant recipients , 2009, Clinical transplantation.

[31]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[32]  S. Webber,et al.  Chronic high Epstein‐Barr viral load carriage in pediatric liver transplant recipients , 2009, Pediatric transplantation.

[33]  V. Dharnidharka,et al.  Post-transplant lymphoproliferative disease , 2009, Pediatric Nephrology.

[34]  M. Ho,et al.  Timing of Epstein-Barr Virus Acquisition and the Course of Posttransplantation Lymphoproliferative Disorder in Children , 2009, Transplantation.

[35]  S. Gupta,et al.  Viral immune monitoring for post‐transplant lymphoproliferative disorder , 2009, Pediatric transplantation.

[36]  J. Fishman Transplantation Microbiology: An Evolving Pillar of Transplant Care , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  R. Hetzer,et al.  Diagnosis and treatment of post‐transplantation lymphoproliferative disorder in pediatric heart transplant patients , 2009, Pediatric transplantation.

[38]  J. Fox,et al.  Interlaboratory Comparison of Epstein‐Barr Virus Viral Load Assays , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  B. Gärtner,et al.  Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone , 2009, Annals of Hematology.

[40]  H. Chi,et al.  Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation. , 2008, Transplantation proceedings.

[41]  Joan W. Miller,et al.  Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction , 2008 .

[42]  B. Einollahi,et al.  Associations of Human Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. , 2007, Annals of transplantation.

[43]  A. Kirk,et al.  Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  B. Dörken,et al.  Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution , 2007, Annals of Hematology.

[45]  J. Pascual Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  H. Fickenscher,et al.  Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. , 2007, The Lancet. Oncology.

[47]  B. Moulin,et al.  Post‐Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French Registry , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[48]  M. Pavlakis,et al.  Retransplantation After Post‐Transplant Lymphoproliferative Disorders: An OPTN/UNOS Database Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[49]  E. González-Barca,et al.  Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation , 2006, Transplantation.

[50]  Boris Katz,et al.  CMV‐IVIG for Prevention of Epstein Barr Virus Disease and Posttransplant Lymphoproliferative Disease in Pediatric Liver Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[51]  G. Opelz,et al.  Disassociation Between Risk of Graft Loss and Risk of Non-Hodgkin Lymphoma With Induction Agents in Renal Transplant Recipients , 2006, Transplantation.

[52]  T. Habermann,et al.  Post‐Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[53]  G. Salles,et al.  Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. , 2006, Blood.

[54]  R. Kotloff,et al.  Management of patients with post‐transplant lymphoproliferative disorder: the role of rituximab , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[55]  A. Humar,et al.  A Randomized Trial of Ganciclovir versus Ganciclovir Plus Immune Globulin for Prophylaxis Against Epstein-Barr Virus Related Posttransplant Lymphoproliferative Disorder , 2006, Transplantation.

[56]  B. Kestenbaum,et al.  Risk of Lymphoma after Renal Transplantation Varies with Time: An Analysis of the United States Renal Data System , 2006, Transplantation.

[57]  M. Pescovitz,et al.  Ganciclovir and Acyclovir Reduce the Risk of Post‐Transplant Lymphoproliferative Disorder in Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[58]  L. Agodoa,et al.  Posttransplant Lymphoproliferative Disorders after Renal Transplantation in the United States in Era of Modern Immunosuppression , 2005, Transplantation.

[59]  D. Dunn,et al.  Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation , 2005, Cancer.

[60]  V. Dharnidharka,et al.  Risk for post‐transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation , 2005, Pediatric transplantation.

[61]  H. Heslop,et al.  Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[62]  S. McDonald,et al.  Lymphoproliferative Disease after Renal Transplantation in Australia and New Zealand , 2005, Transplantation.

[63]  Epstein–Barr virus and lymphoproliferative disorders after transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[64]  G. Snell,et al.  Epstein-Barr Virus Primary Mismatching and HLA Matching: Key Risk Factors for Post Lung Transplant Lymphoproliferative Disease , 2004, Transplantation.

[65]  G. Opelz,et al.  Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[66]  R. Wolfe,et al.  Immunosuppression and the Risk of Post‐Transplant Malignancy Among Cadaveric First Kidney Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  L. Swinnen,et al.  Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1 , 2003, Transplantation.

[68]  David W. Johnson,et al.  A single-centre experience of post-renal transplant lymphoproliferative disorder , 2003, Transplant international : official journal of the European Society for Organ Transplantation.

[69]  V. Shahinian,et al.  Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients1 , 2003 .

[70]  V. Shahinian,et al.  Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. , 2003, Transplantation.

[71]  V. Dharnidharka,et al.  Post‐Transplant Lymphoproliferative Disorder in the United States: Young Caucasian Males are at Highest Risk , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[72]  H. Riess,et al.  Identification of early antigen BZLF1/ZEBRA protein of Epstein–Barr virus can predict the effectiveness of antiviral treatment in patients with post‐transplant lymphoproliferative disease , 2002, British journal of haematology.

[73]  P. Hopkins,et al.  Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[74]  J. Preiksaitis,et al.  Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. , 2002, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[75]  D. Stablein,et al.  RISK FACTORS FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN PEDIATRIC KIDNEY TRANSPLANTATION: A REPORT OF THE NORTH AMERICAN PEDIATRIC RENAL TRANSPLANT COOPERATIVE STUDY (NAPRTCS)1 , 2001, Transplantation.

[76]  Clara D. Bloomfield,et al.  The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. , 2000, The hematology journal : the official journal of the European Haematology Association.

[77]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  R. Busuttil,et al.  Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. , 1998, Transplantation.

[79]  F. Davi,et al.  Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  J. Reyes,et al.  Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[81]  A. Kliger,et al.  Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. , 1997, Transplantation.

[82]  N. Harris,et al.  Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. , 1997, Seminars in diagnostic pathology.

[83]  H. Koeppen,et al.  Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. , 1996, Transplantation.

[84]  T. Habermann,et al.  Pretransplantation assessment of the risk of lymphoproliferative disorder. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  T. Habermann,et al.  Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[86]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[87]  R. Fisher,et al.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.

[88]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.